|
Characteristics
|
Healthy subjects (n = 33)
|
Stage I (n = 16)
|
Stage II (n = 47)
|
Stage III (n = 28)
|
Stage IV (n = 21)
|
|---|
|
Gender (Male, %)
|
17 (51.52 %)
|
6 (37.50 %)
|
29 (61.70 %)
|
12 (42.86 %)
|
8 (38.10 %)
|
|
Age (years)
|
60.72 ± 10.26
|
61.38 ± 11.71
|
63.51 ± 10.50
|
64.38 ± 9.99
|
58.86 ± 12.00
|
|
Albumin (g/l)
|
38.91 ± 4.87
|
33.96 ± 6.71
|
36.22 ± 6.22
|
36.99 ± 6.25
|
36.97 ± 4.62
|
|
Total cholesterol (mM)
|
3.96 ± 0.62
|
3.93 ± 1.14
|
3.85 ± 1.24
|
3.50 ± 0.89
|
3.48 ± 1.17
|
|
Triglycerides (mM)
|
0.94 ± 0.46
|
1.26 ± 0.35
|
1.37 ± 0.80
|
1.31 ± 0.66
|
1.67 ± 0.61
|
|
CEA (ng/ml)
|
ND
|
2.13 (1.08-2.30)
|
4.73 (3.23-18.88)b
|
3.16 (2.55-7.18)b
|
10.54 (8.91-13.64)bcd
|
|
CA199 (U/ml)
|
ND
|
9.45 (5.38-10.19)
|
15.76 (10.73-34.51)b
|
19.43 (10.67-46.56)b
|
64.07 (2.56-779.92)bcd
|
|
Platelet count (109/L)
|
248.35 ± 50.32
|
281.40 ± 94.95
|
259.62 ± 91.42
|
273.79 ± 87.21
|
309.97 ± 77.95
|
|
Erythrocyte count (1012/L)
|
4.35 ± 0.42
|
4.16 ± 0.71
|
4.43 ± 0.83
|
4.50 ± 0.59
|
4.23 ± 0.84
|
|
Hemoglobin (g/L)
|
126.49 ± 20.37
|
117.51 ± 32.60
|
123.81 ± 30.15
|
124.73 ± 27.60
|
120.23 ± 29.76
|
|
PT (s)
|
11.70 ± 0.72
|
10.83 ± 0.70
|
11.86 ± 0.92
|
11.26 ± 0.87
|
11.06 ± 0.81
|
|
APTT (s)
|
31.41 ± 2.85
|
27.14 ± 3.41a
|
27.84 ± 4.01a
|
25.39 ± 2.85abc
|
24.81 ± 2.56abc
|
|
D-dimer (mg/L)
|
0.13 (0.06-0.18)
|
0.31 (0.19-1.07)a
|
0.38 (0.22-1.78)a
|
0.72 (0.32-1.16)abc
|
0.73 (0.29-1.12)abc
|
|
Fibrinogen (g/L)
|
3.47 ± 1.03
|
3.59 ± 1.66
|
3.89 ± 1.19
|
3.42 ± 0.72
|
3.81 ± 0.58
|
|
Current smoking, n (%)
|
5 (15.15 %)
|
2 (12.50 %)
|
9 (19.15 %)
|
6 (21.43 %)
|
5 (23.81 %)
|
|
Thrombotic events, n (%)
|
2 (6.06 %)
|
3 (18.75 %)a
|
10 (21.28 %)a
|
9 (32.14 %)a
|
6 (28.57 %)a
|
- Data are expressed by mean ± standard deviation [SD], percentage or median (interquartile range [IQR]). PT prothrombin time, APTT activated partial thromboplastin time. ND not determined. a
P < 0.05 versus healthy controls, b
P < 0.05 versus stage I, c
P < 0.05 versus stage II. d
P < 0.01 versus stage III
